Cidel Asset Management Inc. Boosts Stake in CVS Health Corporation $CVS

Cidel Asset Management Inc. increased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 16.0% during the first quarter, HoldingsChannel.com reports. The fund owned 39,565 shares of the pharmacy operator’s stock after buying an additional 5,467 shares during the period. Cidel Asset Management Inc.’s holdings in CVS Health were worth $2,842,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $28,000. Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the fourth quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC acquired a new position in CVS Health during the fourth quarter worth $29,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. HSBC upped their target price on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a report on Tuesday, May 5th. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Leerink Partners reissued an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research note on Thursday, June 11th. Finally, Truist Financial boosted their target price on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a report on Monday, June 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $101.28.

CVS Health Price Performance

CVS Health stock opened at $101.68 on Wednesday. The company’s 50 day simple moving average is $90.21 and its 200-day simple moving average is $81.86. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $103.12. The company has a market capitalization of $129.74 billion, a price-to-earnings ratio of 44.79, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter last year, the firm earned $2.25 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Pharmacy is expanding GLP-1 support across more than 9,000 locations and MinuteClinic, including lower costs, access help, and therapy support, which could boost patient engagement and prescription volume. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: CVS is adding a new $49 virtual MinuteClinic visit and broader weight-management support, reinforcing growth in its consumer health services. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: Traders bought an unusually large number of CVS call options, suggesting bullish sentiment in the stock.
• Positive Sentiment: Third-party research pieces highlighted CVS as a top-ranked value and long-term momentum stock, which may be supporting investor confidence. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Positive Sentiment: CVS also received upbeat coverage for expanding its GLP-1 support, helping explain the stock’s recent outperformance. CVS Health Expands GLP-1 Support for Patients
• Neutral Sentiment: CVS highlighted community and public-health initiatives, including HIV awareness and a grand opening event in New Jersey, but these are unlikely to move the stock materially. CVS Health: Thank You! Mews at St. Mary Grand Opening – Williamstown, NJ
• Neutral Sentiment: Articles noting CVS was “under the microscope” after a healthcare report could keep some regulatory scrutiny in focus, but the details provided do not indicate an immediate financial hit. CVS Health (CVS) Under the Microscope After Recent Healthcare Report

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.